ClinicalTrials.gg
Not yet recruitingNCT07847398EMMENEO-TNUpdated Sep 29, 2026

Emergence of Predictive Metabolomic Biomarkers of Response to Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer.

An interventional study of Blood sampling and Tumor sampling in Triple-negative Breast Cancer (TNBC), Stage II-III, sponsored by Centre Antoine Lacassagne. Not yet recruiting at 1 site in France. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by Centre Antoine Lacassagne · Not applicable, Interventional, and Diagnostic

How we know

Updated Sep 29, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 125 studies in Triple Negative Breast Neoplasms with a site in France — 35 open to participants now, 66 under way, 13 of them phase 3. Triple Negative Breast Neoplasms · France.

Planned enrollment
101st of 119
50 · median 182
Started
2026
with 6 others
No phase
14 of 125
8 open now
Primary completion
2029-05
later than 45 of 65 live
Registered
124th of 125
by date

Among the 125 studies in Triple Negative Breast Neoplasms with a site in France, this one is the 101st largest by planned enrollment of the 119 interventional ones that give a count, is one of 7 that started in 2026, is one of 14 with no phase, reaches primary completion later than 45 of the 65 other live ones, and was the 124th registered.

Triple Negative Breast Neoplasms

1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 441 are open to participants now.

Browse Triple Negative Breast Neoplasms studies →

Open to participants now

35 of the 125 studies in Triple Negative Breast Neoplasms with a site in France are open now. Recruiting first, the newest first:

30 more — sign in →

All 35 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 329 Triple Negative Breast Neoplasms studies recruiting now, 229 (70%) set no upper age limit and 85 (26%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 125 studies in Triple Negative Breast Neoplasms with a site in France, or all of them as a file.
02

Study summary

The goal of this study is to investigate whether specific metabolic profiles can predict response to neoadjuvant chemo-immunotherapy in patients with stage II and III triple-negative breast cancer (TNBC).

The main objectives are to determine:

  • whether targeted metabolic pathways, specifically tryptophan and diacetylspermine metabolism, are associated with histological response to neoadjuvant treatment;
  • whether untargeted metabolomics combined with machine learning approaches can identify novel biomarkers predictive of treatment response.

Participants will:

  • undergo image-guided tumor sampling during the standard-of-care placement of the tumor localization clip, prior to initiation of neoadjuvant chemo-immunotherapy, in accordance with routine clinical practice at the study center;
  • provide a blood sample before initiation of neoadjuvant chemo-immunotherapy;
  • provide a second blood sample during the course of standard treatment; continue to receive routine clinical care, including imaging assessments and surgical management, according to standard clinical practice.

The study does not modify the patient's standard therapeutic management.

03

Conditions studied

  • Triple-negative Breast Cancer (TNBC), Stage II-III
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or older.
  • Female patient with stage II and III triple-negative breast cancer, requiring chemo-immunotherapy according to the KEYNOTE-522 regimen or any neoadjuvant treatment including chemotherapy and immunotherapy validated in standard care or a clinical trial, regardless of the treatment regimen (ER \< 10%, PR \< 10%, 0, and HER2 low).
  • Patient requiring the placement of a localization clip as part of their standard clinical care management.
  • Patient who has read the information sheet and signed the .
  • Patient affiliated with a Social Security health insurance scheme.

Exclusion criteria

Exclusion Criteria:

  • breast cancer documented by staging workup (PET scan or thoraco-abdomino-pelvic CT scan + bone scan).
  • Patient who has undergone primary surgery.
  • \< 1.5; \< 50,000/$\mu$L.
  • Patient presenting with multiple primary malignant tumors.
  • Patient with infection, , or active .
  • Patient taking:
  • Dual antiplatelet therapy: Acetylsalicylic acid + Clopidogrel without the possibility of suspending Clopidogrel for 5 days,
  • Ticagrelor without the possibility of suspension for 5 days,
  • Prasugrel without the possibility of suspension for 7 days,
  • Vitamin K antagonists (acenocoumarol, warfarin, or fluindione) with INR \< 2 or > 3, without the possibility of suspension.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Neoadjuvant chemo-immunotherapy

    Patients receiving neoadjuvant chemo-immunotherapy according to the study protocol.

    Biological: Blood sampling · Procedure: Tumor sampling

Interventions

  • BiologicalBlood sampling

    Two blood samples will be collected during neoadjuvant chemo-immunotherapy: one at Cycle 1, Day 1 (C1D1) of Sequence 1, prior to treatment initiation, and one at Cycle 3, Day 1 (C3D1) of Sequence 2, prior to treatment administration. Blood samples will be used for metabolomic analyses of plasma.

  • ProcedureTumor sampling

    Two tumor core biopsy samples will be collected under radiological guidance during placement of the localization clip, prior to initiation of neoadjuvant chemo-immunotherapy, in accordance with standard procedures at the study site. One core will be used for pathological confirmation of tumor tissue and the other will be collected for research purposes and used for subsequent molecular analyses.

06

What researchers measure

Primary outcomes

  1. Predictive performance of targeted metabolites and histological response

    The predictive performance of targeted metabolites (tryptophan pathway and diacetylspermine) to predict post-surgical histological response will be evaluated using the area under the ROC curve (AUC), with an AUC target \> 0.8. Histological response will be assessed according to the Residual Cancer Burden (RCB) classification, ranging from RCB0 (pathological complete response) to RCB3 (presence of extensive residual disease), based on the results obtained from the surgical specimen of breast surgery.

    Time frame: From enrollment to the end of treatment and follow-up - 8 months.

  2. Consistency of metabolites between plasma and tumor biopsies

    The consistency of variations in metabolites of interest between plasma samples and tumor biopsies will be evaluated by a semi-quantitative correlation between the two compartments.

    Time frame: From enrollment to the end of treatment and follow-up - 8 months.

Secondary outcomes

  1. Performance of a metabolomic signature using machine learning

    The performance of a metabolomic signature (untargeted analysis), established notably using machine learning methods, to predict post-surgical histological response will be evaluated by the AUC, with a target \> 0.8.

    Time frame: From enrollment to the end of treatment and follow-up - 8 months.

  2. Variations of tryptophan pathway metabolites

    Variations in tryptophan pathway metabolites will be evaluated by semi-quantitative correlation with the clinical-biological response.

    Time frame: From enrollment to the end of treatment and follow-up - 8 months.

  3. Prediction of radiological response by targeted metabolites

    The predictive performance of targeted metabolites to predict radiological response to neoadjuvant chemo-immunotherapy will be evaluated by the AUC, with a target \> 0.8.

    Time frame: From enrollment to the end of treatment and follow-up - 8 months.

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for May 2029, 31 months later.

Of 49 interventional studies with no phase under Triple Negative Breast Neoplasms, half reached primary completion within 82 months of starting (the median), counting those still running; a quarter within 36. This study's planned 31 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 17, 2026
First posted
Sep 29, 2026
StartEst.
Oct 2026
Primary completionEst.
May 2029
CompletionEst.
May 2029
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07847398
Lead sponsor
Centre Antoine Lacassagne
Responsible party
Sponsor
First posted
Sep 29, 2026
Start date
Oct 2026 (estimated)
Primary completion
May 2029 (estimated)
Completion
May 2029 (estimated)
Last update
Sep 29, 2026

Study contacts

Study coordinator
Contact
DRCI-Promotion@nice.unicancer.fr
+33 (0)4 92 03 17 78
Caroline BAILLEUX
principal investigator · Centre Antoine Lacassagne

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion